Twice-yearly antibody shows strong therapeutic potential for weight-loss
iBio has announced new preclinical data from its obese non-human primate (NHP) study evaluating IBIO-610, potentially a first-in-class Activin E antibody candidate supported by preclinical data.
The findings will be presented during an oral session at ObesityWeek 2025, taking place 4-7 November in Atlanta, USA.
“GLP-1 therapies have transformed the treatment for obesity, but gaps in patient care remain for durable options addressing biology beyond appetite control,” said Martin Brenner, Chief Executive Officer and Chief Scientific Officer of iBio. “Our AI-enabled discovery platform has accomplished what was long considered extremely difficult – creating potentially a first-in-class long-acting antibody against Activin E. We believe this modality offers deep, sustained pathway blockade with infrequent dosing while leveraging the scalability and reliability of the global antibody manufacturing infrastructure.”
The pharmacokinetic data demonstrate IBIO-610 has an extended half-life in obese non-human primates of 33.2 days. Based on an allomeric scaling model of half-life extended antibodies it is predicted IBIO-610 will have a half-life in humans of up to 100 days, reducing the dosing frequency to once every six months, which has the potential to significantly improve patient experience.
“We are encouraged by these findings, as the combination of extended half-life and strong mechanistic validation in our mouse models underscores the differentiated profile of IBIO-610,” said Dr Cory Schwartz, Director of Research and Early Development of iBio. “We believe that antibody-mediated targeting of Activin E has the potential to enable more comprehensive pathway modulation than other therapeutic approaches for the treatment of obesity. With its long-acting profile and fat-selective biology, IBIO-610 could not only promote fat-selective weight loss but also serve as an option for individuals transitioning off GLP-1 therapies, helping them maintain results without frequent injections, daily pills, or the side effects associated with GLP-1 agonism.”
Diana Turner, Deputy Editor, DDW
